查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023-2030年全球照護端分子診斷市場
市場調查報告書
商品編碼
1296870

2023-2030年全球照護端分子診斷市場

Global Point of Care Molecular Diagnostics Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 100 Pages | 商品交期: 2-3個工作天內

價格

分段展望

全球照護端分子診斷市場根據其應用、終端用戶和技術進行細分。基於應用，市場被分為流感、單核細胞增多症、呼吸道傳染病、胃腸道傳染病、性傳播疾病和其他（產前檢測和內分泌）。基於終端用戶，市場被分類為醫院、家庭護理和其他（分散的實驗室）。基於技術，市場被分為PCR、基因測序、雜交和微陣列。基於技術，PCR部分預計將以良好的速度成長。成長的原因是PCR在蛋白質組學、基因組學和COVID-19測試中的使用越來越多，因為它是易於使用的設備是推動這一細分市場成長的主要因素。

單核細胞增多症部分預計將以有利的速度成長

基於應用，單核細胞增多症部分在預測期內佔據了重要的市場佔有率。導致單核細胞增多的主要因素包括健康意識的提高、單核細胞增多症的病例以及青少年人口的增加。此外，傳染性單核細胞增多症大多影響15至24歲的青少年和年輕人（每千人年6至8例），特別是那些生活在公共環境中的人，如宿舍或軍營，根據美國心臟協會，每千人有近11至48例被單核細胞增多症感染。

區域展望

全球照護端分子診斷市場根據地域進一步細分，包括北美（美國和加拿大）、歐洲（義大利、西班牙、德國、法國和其他）、亞太（印度、中國、日本、韓國和其他）和世界其他地區（中東和非洲以及拉丁美洲）。根據地理區域，市場被分類為北美、歐洲、亞太和世界其他地區。由於人口基數較大，而且有潛在的具有成本效益的照護端分子診斷測試的實施，預計亞太地區將在預測期內見證最快的成長。

2023-2030年全球照護端分子診斷市場成長，按地區分類

資料來源：OMR分析

北美地區引領全球照護端分子診斷市場的成長

癌症病例的增加和完善的醫療系統是推動市場成長的突出因素根據美國癌症協會的數據，2021年，美國有1,898,160個新診斷的癌症病例和608,570個癌症死亡率。此外，傳染病的高發率，以及主要市場參與者通過建立夥伴關係、合作和資助戰略提供分子診斷測試，預計將促進市場成長。例如，2021年12月，Spesana、EMR和Biodesix公司，宣布他們已經合作，利用Spesana的數位平台解決方案，在全美的臨床工作流程中進一步簡化和自動化分子診斷的使用，進行全面的肺癌管理。 Spesana雲端基礎數位醫療平台統一了所有的EMR、實驗室資訊系統和分子診斷，以改善通常被認為是破碎的電子醫療系統，該系統經常將本應簡單的任務變成醫療服務提供者的複雜問題。

\市場參與者展望

對全球照護端分子診斷市場做出貢獻的主要公司包括雅培實驗室、Becton, Dickinson and Co., Bosch Healthcare Solutions GmbH, Siemens Healthineers, Thermo Fisher Scientific Inc., Enzo Biochem, Eurofins Scientific, Fluxergy等。市場參與者通過採取各種成長戰略，包括推出新產品、合併和收購、與政府合作以及技術進步來保持市場競爭力，大大促進了市場成長。例如，2023年3月，全球基金、美國國際開發署和杜絕結核病夥伴關係與Molbio診斷公司達成合作，後者是照護端分子診斷公司和全球知名的Truenat平台的發明者。這種合作關係有助於使受影響的患者獲得及時和準確的診斷設置，從而幫助Molbio實現其通過Truenat平台提供完整的測試解決方案的目標。

該報告包括：

  • 2022年的市場價值數據分析和對2030年的預測。
  • 每個市場部分的年化市場收入（百萬美元）。
  • 主要地理區域的國別分析。
  • 在全球照護端分子診斷市場運作的主要公司。基於數據的可用性，報告中還提供了與新產品發布有關的資訊，以及相關的新聞。
  • 通過識別定位在未來強勁成長的關鍵市場領域來分析商業戰略。
  • 分析市場進入和市場擴張戰略。
  • 通過確定市場中的"誰站在哪裡"來分析競爭策略。

目錄

第一章：報告摘要

  • 當前行業分析和成長潛力展望
  • 研究應用和工具
  • 市場細分
    • 按領域分類
    • 按地區

第二章：市場概述和洞察力

  • 報告的範圍
  • 分析師的洞察力和當前的市場趨勢
    • 主要發現
    • 建議
    • 總結

第三章：競爭格局

  • 主要公司分析
  • Abbott Laboratories
    • 概述
    • 財務分析
    • SWOT分析
    • 近期發展情況
  • Becton, Dickinson and Co.
    • 概況
    • 財務分析
    • SWOT分析
    • 近期發展情況
  • Bosch Healthcare Solutions GmbH
    • 進展概況
    • 財務分析
    • SWOT分析
    • 近期發展情況
  • Siemens Healthineers
    • 進展概況
    • 財務分析
    • SWOT分析
    • 近期發展情況
  • Thermo Fisher Scientific Inc.
    • 進展概況
    • 財務分析
    • SWOT分析
    • 近期發展
  • 關鍵戰略分析

第四章：市場細分

  • 全球照護端分子診斷市場的應用情況
    • 流感
    • 單核細胞增多症
    • 呼吸道感染性疾病
    • 胃腸道傳染病
    • 性傳播疾病
    • 其他（產前檢查和內分泌學）。
  • 按終端用戶分類的全球照護端分子診斷市場
    • 醫院
    • 家庭護理
    • 其他（分散的實驗室）
  • 按技術分類的全球照護端分子診斷市場
    • PCR
    • 基因測序
    • 雜交技術
    • 微陣列

第五章：區域分析

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 世界其他地區

第六章：公司簡介

  • Accelerate Diagnostics
  • Access Bio
  • Ador Diagnostics
  • ADT Biotech
  • Akonni Biosystems
  • Alveo Technologies
  • Antelope Dx
  • Applied BioCode
  • Aureum Diagnostics
  • Aus Diagnostics
  • Baebies
  • Beckman Coulter Diagnostics
  • Binx Health
  • Biocartis
  • BioFire Diagnostics (bioMerieux)
  • BioMerieux Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Cepheid (Danaher)
  • Credo Diagnostics Biomedical
  • Cue Health
Product Code: OMR2027362

Title:Global Point of Care Molecular Diagnostics Market Size, Share & Trends Analysis Report by Application (Influenza, Mononucleosis, Respiratory Infectious Disease, Gastrointestinal Infectious Disease, Sexually Transmitted Disease, and Others (prenatal testing, and endocrinology)), by End User (Hospitals, Homecare, and Others (decentralized labs)), and by Technology (PCR, Genetic Sequencing, Hybridization, and Microarray) Forecast Period (2022-2030).

Global point of care molecular diagnostics market is estimated to grow at a CAGR of 8.2% during the forecast period. Increased R&D funding for technologies that will reduce clinical diagnostic testing time is driving growth in the point-of-care molecular diagnostics market. Notably, the COVID-19 pandemic has driven greater willingness by regulatory authorities to fast-track approval of diagnostic products. For instance, in April 2020, the US National Institutes of Health (NIH) Point-of-Care Technologies Research Network (POCTRN) launched the Rapid Acceleration of Diagnostics (RADxSM) initiative. The initiative accelerates the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to clinical laboratory tests, that can directly detect SARS-CoV-2. In addition, the increased prevalence of chronic diseases that require long-term outpatient care, rapid shifts in government and research funding, and exciting advancements in life science technologies are the major factors that further boost the market growth. According to the Center for Disease Control and Prevention (CDC), almost half of all American adults have high blood pressure, and cardiovascular disease is responsible for one in three deaths, nearly 859,000 people in the US suffered from various chronic diseases in 2022.

Segmental Outlook

The global point of care molecular diagnostics market is segmented based on its application, end user, and technology. Based on application, the market is divided into Influenza, Mononucleosis, Respiratory Infectious Disease, Gastrointestinal Infectious Disease, Sexually Transmitted Diseases, and Others (prenatal testing, and endocrinology). Based on end user, the market is segmented into hospitals, homecare, and others (decentralized labs). Based on technology, the market is categorized into PCR, genetic sequencing, hybridization, and microarray. Based on technology, the PCR segment is projected to grow at a favorable rate. The growth is attributed to the growing use of PCR in proteomics, genomics, and COVID-19 testing, as it is easy-to-use devices are the major factors driving the growth of this market segment.

The Mononucleosis segment is Projected to Grow at a Favorable Rate

Based on application, the Mononucleosis segment holds a significant market share in the market during the forecast period. The major factors responsible for the growth of mononucleosis include rising health awareness, increasing mononucleosis cases, and the rise in the adolescent population. Moreover, infectious mononucleosis mostly affects adolescents and young adults 15 to 24 years of age (6 to 8 cases per 1,000 person-years), particularly those living in communal environments, such as dormitories or military barracks, nearly 11 to 48 cases per 1,000 people were infected by mononucleosis according to the American Heart Association.  

Regional Outlooks

The global point of care molecular diagnostics market is further segmented based on geography, including North America (the US and Canada), Europe (Italy, Spain, Germany, France, and others), Asia-Pacific (India, China, Japan, South Korea, and others), and the Rest of the World (the Middle East & Africa and Latin America). Based on geography, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World. Asia Pacific is expected to witness the fastest growth over the forecast period owing to a larger population base, and availability of potential cost-effective implementation of point of care molecular diagnostics tests.

Global Point of Care Molecular Diagnostics Market Growth, by Region 2023-2030

Source: OMR Analysis

The North American Region Leads the Growth of the Global Point of Care Molecular Diagnostics Market

Increasing cases of cancer and well-established healthcare systems are the prominent factors that drive market growth According to the American Cancer Society, in 2021, there were 1,898,160 new cancer cases diagnosed and 608,570 cancer mortality in the US. In addition, the high prevalence of infectious diseases, and the presence of major market players that are offering molecular diagnostics tests by entering into partnership, collaboration, and funding strategy, is projected to boost market growth. For instance, in December 2021, Spesana, EMRs, and Biodesix Inc., announced that they have partnered to further streamline and automate the use of molecular diagnostics in clinical workflows across the US utilizing Spesana's digital platform solutions for comprehensive lung cancer management. Spesana cloud-based Digital Healthcare Platform unifying all EMRs, Lab Information Systems and Molecular Diagnostics to improve what is often considered a broken electronic healthcare system that all too frequently turns what should be simple tasks into complex problems for healthcare providers.

\Market Players Outlook

Major companies contributing to the global point of care molecular diagnostics market include Abbott Laboratories, Becton, Dickinson and Co., Bosch Healthcare Solutions GmbH, Siemens Healthineers, Thermo Fisher Scientific Inc., Enzo Biochem, Eurofins Scientific, Fluxergy, and others. The market players are considerably contributing to the market growth by adopting various growth strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market. For instance, in March 2023, Global Fund, USAID and Stop TB partnership entered into a collaboration with Molbio Diagnostics, point-of-care molecular diagnostics company and inventor of the globally renowned Truenat platform. This partnership help democratize and increase access to timely and accurate diagnostic settings to affected patients, thus helping Molbio achieve its goal of providing complete testing solutions via the Truenat platform.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global point of care molecular diagnostics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Application s and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight and Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 1.1. Key Company Analysis
  • 3.1. Abbott Laboratories
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Becton, Dickinson and Co.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Bosch Healthcare Solutions GmbH
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Siemens Healthineers
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Thermo Fisher Scientific Inc.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Point of Care Molecular Diagnostics Market by Application
    • 4.1.1. Influenza
    • 4.1.2. Mononucleosis
    • 4.1.3. Respiratory Infectious Disease
    • 4.1.4. Gastrointestinal Infectious Disease
    • 4.1.5. Sexually Transmitted Disease
    • 4.1.6. Others (prenatal testing, and endocrinology)
  • 4.2. Global Point of Care Molecular Diagnostics Market by End user
    • 4.2.1. Hospitals
    • 4.2.2. Homecare
    • 4.2.3. Others (decentralized labs)
  • 4.3. Global Point of Care Molecular Diagnostics Market by Technology
    • 4.3.1. PCR
    • 4.3.2. Genetic Sequencing
    • 4.3.3. Hybridization
    • 4.3.4. Microarray

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. US
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Accelerate Diagnostics
  • 6.2. Access Bio
  • 6.3. Ador Diagnostics
  • 6.4. ADT Biotech
  • 6.5. Akonni Biosystems
  • 6.6. Alveo Technologies
  • 6.7. Antelope Dx
  • 6.8. Applied BioCode
  • 6.9. Aureum Diagnostics
  • 6.10. Aus Diagnostics
  • 6.11. Baebies
  • 6.12. Beckman Coulter Diagnostics
  • 6.13. Binx Health
  • 6.14. Biocartis
  • 6.15. BioFire Diagnostics (bioMerieux)
  • 6.16. BioMerieux Diagnostics
  • 6.17. Bio-Rad Laboratories, Inc.
  • 6.18. Cepheid (Danaher)
  • 6.19. Credo Diagnostics Biomedical
  • 6.20. Cue Health

LIST OF TABLES

  • 1. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 2. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS FOR INFLUENZA MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS FOR MONONUCLEOSIS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS FOR RESPIRATORY INFECTIOUS DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS FOR GASTROINTESTINAL INFECTIOUS DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS FOR SEXUALLY TRANSMITTED DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS FOR OTHERS (PRENATAL TESTING, AND ENDOCRINOLOGY) MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 9. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS IN HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS IN HOMCARE MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS IN OTHERS (DECENTRALIZED LABS) MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 13. GLOBAL PCR POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL GENETIC SEQUENCING POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. GLOBAL HYBRIDIZATION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. GLOBAL MICROARRAY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 17. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 19. NORTH AMERICAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION , 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 21. NORTH AMERICAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY , 2022-2030 ($ MILLION)
  • 22. EUROPEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 23. EUROPEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION , 2022-2030 ($ MILLION)
  • 24. EUROPEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 25. EUROPEAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 26. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 27. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 28. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 29. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY , 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2022-2030 ($ MILLION)
  • 32. REST OF THE WORLD POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END USER , 2022-2030 ($ MILLION)
  • 33. REST OF THE WORLD POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY , 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SHARE BY APPLICATION, 2022 VS 2030 (%)
  • 2. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS FOR INFLUENZA MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS FOR MONONUCLEOSIS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS FOR RESPIRATORY INFECTIOUS DISEASE MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS FOR GASTROINTESTINAL INFECTIOUS DISEASE MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS FOR SEXUALLY TRANSMITTED DISEASE MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS FOR OTHERS (PRENATAL TESTING, AND ENDOCRINOLOGY) MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SHARE BY END USER, 2022 VS 2030 (%)
  • 9. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS IN HOSPITALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS IN HOMECARE MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS IN OTHERS (DECENTRALIZED LABS) MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SHARE BY TECHNOLOGY, 2022 VS 2030 (%)
  • 13. GLOBAL PCR POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL GENETIC SEQUENCING POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL HYBRIDIZATION POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL MICROARRAY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 17. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 18. US POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. UK POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. REST OF EUROPE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. INDIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. CHINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. JAPAN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. SOUTH KOREA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. REST OF ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)